ChiCTR2500097650 版本V1.0 版本创建时间2025/02/24 09:10:33 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500097650 

最近更新日期:

Date of Last Refreshed on:

2025-02-24 09:10:28 

注册时间:

Date of Registration:

2025-02-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

间歇阻断肾动脉技术减轻肾部分切除术后肾脏损伤的临床研究

Public title:

Clinical study on the application of intermittent renal artery occlusion technique in reducing renal injury after partial nephrectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

间歇阻断肾动脉技术减轻肾部分切除术后肾脏损伤的临床研究

Scientific title:

Clinical study on the application of intermittent renal artery occlusion technique in reducing renal injury after partial nephrectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李怀康 

研究负责人:

马鑫 

Applicant:

Li Huaikang 

Study leader:

Ma Xin 

申请注册联系人电话:

Applicant telephone:

+86 157 0157 1812

研究负责人电话:

Study leader's
telephone:

+86 138 0122 1736

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hkli301@126.com

研究负责人电子邮件:

Study leader's E-mail:

mxin301@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区永定路69号

研究负责人通讯地址:

北京市海淀区永定路69号

Applicant address:

No. 69, Yongding Road, Haidian District, Beijing, China

Study leader's address:

No. 69, Yongding Road, Haidian District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100039

研究负责人邮政编码:

Study leader's postcode:

100039

申请人所在单位:

中国人民解放军总医院第三医学中心

Applicant's institution:

The Third Medical Center, Chinese PLA General Hospital

研究负责人所在单位:

中国人民解放军总医院第三医学中心

Affiliation of the Leader:

The Third Medical Center, Chinese PLA General Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审科研第(KY2024-039)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军总医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Chinese PLA General Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-12 00:00:00

伦理委员会联系人:

陈然

Contact Name of the ethic committee:

Chen Ran

伦理委员会联系地址:

北京市海淀区永定路69号

Contact Address of the ethic committee:

No. 69, Yongding Road, Haidian District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 5797 6902

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军总医院第三医学中心

Primary sponsor:

The Third Medical Center, Chinese PLA General Hospital

研究实施负责(组长)单位地址:

北京市海淀区永定路69号

Primary sponsor's address:

No. 69, Yongding Road, Haidian District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

北京

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

中国人民解放军总医院第三医学中心

具体地址:

北京市海淀区永定路69号

Institution
hospital:

The Third Medical Center, Chinese PLA General Hospital

Address:

No. 69, Yongding Road, Haidian District, Beijing, China

经费或物资来源:

研究者自筹

Source(s) of funding:

Self-funded by researchers

研究疾病:

肾损伤  

Target disease:

Renal injury

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察间歇阻断肾动脉技术对外科缺血性肾损伤的保护作用,为间歇阻断肾动脉技术在肾部分切除术(partial nephrectomy, PN)中应用提供临床研究证据支持。以期实现最大限度地肾脏结构重建与功能保留,最终提高PN患者术后生活质量,节约医疗成本,减轻家庭及社会负担。  

Objectives of Study:

Our study aims to explore how intermittent renal artery occlusion (IRAO) technique protects against surgical ischemic renal injury and to provide clinical evidence for its use in partial nephrectomy (PN). Our ultimate goal is to maximize renal structure recovery and function preservation, improving PN patients' postoperative quality of life, cutting medical costs, and easing the burden on families and society.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、拟行肾部分切除术的单侧肾脏多发肿瘤患者;2、 患者年龄18-75岁之间,无精神性疾病,能配合医生治疗;3、理解并自愿签署书面知情同意书。

Inclusion criteria

1.Patients with unilateral multifocal renal tumors who are candidates for partial nephrectomy; 2.Patients aged between 18 and 75 years, without mental illness, and able to cooperate with the doctor's treatment; 3.Patients who understand and voluntarily sign a written informed consent form.

排除标准:

1、不宜行肾部分切除术的患者;2、肾移植术后;3、合并严重内分泌,造血系统疾病; 4、Ⅱ级以上严重的心功能不全;5、患者预期寿命较短;6、因其他原因医师不建议行该治疗方案的患者。

Exclusion criteria:

1.Patients who are not suitable for partial nephrectomy; 2.Patients who have undergone renal transplantation; 3.Patients with severe endocrine or hematopoietic system disorders; 4.Patients with severe cardiac insufficiency of Grade II or above; 5.Patients with a short expected lifespan; 6.Patients for whom the physician does not recommend this treatment plan due to other reasons.

研究实施时间:

Study execute time:

From 2024-12-01 00:00:00 To 2028-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-03-01 00:00:00 To 2028-11-30 00:00:00

干预措施:

Interventions:

组别:

持续阻断肾动脉组

样本量:

16

Group:

Continuous renal artery occlusion group

Sample size:

干预措施:

持续阻断肾动脉

干预措施代码:

Intervention:

Continuous renal artery occlusion

Intervention code:

组别:

间断阻断肾动脉组

样本量:

16

Group:

Intermittent renal artery occlusion group

Sample size:

干预措施:

间断阻断肾动脉

干预措施代码:

Intervention:

Intermittent renal artery occlusion

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

北京 

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

中国人民解放军总医院第三医学中心 

单位级别:

三甲 

Institution
hospital:

The Third Medical Center, Chinese PLA General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后患肾分肾功能

指标类型:

主要指标

Outcome:

Postoperative renal function of the operated kidney

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后总肾功能

指标类型:

次要指标

Outcome:

Postoperative overall renal function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后24个月肾萎缩发生率(增强CT检测肾皮质体积变化)

指标类型:

次要指标

Outcome:

Incidence rate of renal atrophy 24 months postoperatively (assessed by changes in renal cortical volume via enhanced CT)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由该试验联系人将符合入组的患者按照入组时间先后顺序标记为1-32号,与随机数表产生的32个数字按顺序一一匹配,然后将随机数表产生的32个数字按大小顺序重新排列,前16个数字匹配的患者加入持续阻断肾动脉组,后16个数字匹配的患者加入间断阻断肾动脉组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The contact person for the trial labeled eligible patients in the order of their enrollment as numbers 1 to 32. These numbers were then sequentially matched with 32 random numbers generated from a random number table. Afterward, the 32 random numbers were rearranged in ascending order. Patients matched with the first 16 numbers were assigned to the continuous renal artery occlusion group, while those matched with the last 16 numbers were assigned to the intermittent renal artery occlusion group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2030.12.01通过中国临床试验注册中心共享原始数据,其网址是https://www.chictr.org.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

On December 1, 2030, the raw data will be shared through the Chinese Clinical Trial Registry, whose website is https://www.chictr.org.cn/.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1.病例记录表;2.电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1.Case Record Form, (CRF), 2.Electronic Data Capture,( EDC)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-02-24 09:10:28